Samsung Bioepis Q3 2026 Report: US Biosimilar Market Reaches 96 Approvals, 47% Average Market Share
核心洞察
As of June 2026, 96 biosimilars across 21 unique biological molecules have been approved in the US, with 71 (74%) launched in the market.
Biosimilars have achieved an average 47% market share and reduced Average Sales Price by 52% within five years of initial launch.
Immunology biosimilars including adalimumab, tocilizumab, and ustekinumab showed 25% year-over-year growth in average market penetration.
Samsung Bioepis (搜索) Co., Ltd. has released its Third Quarter 2026 Biosimilar Market Report, the fourteenth edition of its quarterly analysis tracking the United States biosimilar landscape. The report, published July 23, 2026, provides a comprehensive overview of approval and launch status, pricing dynamics including Average Sales Price (ASP) and Wholesale Acquisition Cost (WAC), and market uptake across all biosimilars available in the US.
Thomas Newcomer, Senior Vice President and Head of US Commercial at Samsung Bioepis (搜索), commented on the release: "We are pleased to present the 14th edition of our Biosimilar Market Report, offering our latest analysis of US pricing and market share dynamics across key biosimilar markets. The US drug pricing landscape continues to shift toward greater transparency and accountability. Our report continues to offer an in-depth perspective on current market trends, challenges, and strategic opportunities for stakeholders navigating this rapidly changing landscape."
Market Growth and Penetration
As of June 2026, a total of 96 biosimilars across 21 unique biological molecules have been approved in the United States, with 71 biosimilars—representing 74% of approved products—having launched in the market. The report highlights that biosimilars continue to drive meaningful competition, reaching an average 47% market share and reducing Average Sales Price by 52% within five years of initial launch.
Immunology Biosimilars Show Strong Momentum
Immunology biosimilars within five years of launch—specifically adalimumab, tocilizumab, and ustekinumab—demonstrated robust growth, with average biosimilar market penetration increasing by 25% year over year. Notably, ustekinumab biosimilar penetration is increasing at a significantly faster pace compared to adalimumab biosimilars, despite both being immunology products mainly covered under the pharmacy benefit.
Pricing Trends and Notable Observations
The report identified selected biosimilars that demonstrated sharp ASP increases. Among these, a bevacizumab biosimilar was able to sustain its market share despite the price increase, while a ranibizumab biosimilar experienced an ASP increase following its commercialization partner transition.
340B Drug Pricing Program Reform
This edition's Deep Dive section examines the 340B Drug Pricing Program reform and its potential implications for the biosimilar market, reflecting the evolving regulatory and pricing environment that stakeholders must navigate.
Samsung Bioepis (搜索), established in 2012, is a biopharmaceutical company advancing a pipeline of biologic candidates across therapeutic areas including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.